Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2020

Year

Elizabeth A. Mittendorf, Hong Zhang, Carlos H. Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L. Telli,

The Lancet

Breast OncologyOncologyBreast CancerPharmacotherapyCancer TreatmentMedicineRadiation OncologyMolecular OncologyNeoadjuvant Atezolizumab